Michael Vala, PharmD

Michael Vala, PharmD, is a PGY-2 infectious diseases pharmacy resident at Beth Israel Deaconess Medical Center in Boston, Massachusetts, who is interested in transplant infectious diseases and mycobacterial infections.

Articles by Michael Vala, PharmD

Is Renal-Adjusted Ceftazidime/Avibactam in Patients With KPC-Producing Klebsiella Pneumoniae Bloodstream Infection Associated With Increased Mortality?

ByMichael Vala, PharmD

April 23rd 2025

Do We Have New Data for Optimal Treatments of Candida-Related Prosthetic Joint Infections?

ByYingsi(Vincy) Fang, PharmD, BSC,Michael Vala, PharmD

January 14th 2025

The choice between debridement and implant exchange affects treatment outcomes for Candida-related prosthetic joint infections, highlighting the need for standardized guidelines and further research.

Michael Vala, PharmD

Articles by Michael Vala, PharmD

Is Renal-Adjusted Ceftazidime/Avibactam in Patients With KPC-Producing Klebsiella Pneumoniae Bloodstream Infection Associated With Increased Mortality?

Do We Have New Data for Optimal Treatments of Candida-Related Prosthetic Joint Infections?

Latest Updated Articles

Trending on Contagion Live

Measles Update: February 6, 2026

Pritelivir Improves Outcomes in Immunocompromised Patients With Refractory Herpes Simplex Virus

HIV in the Black Community: Shifting from Stigma and Health Inequalities to Communication and Care Initiatives

Antibiotics Deconstructed: IV Fosfomycin

PASTEUR Act Reintroduced in Congress